Croda International (LSE:CRDA) has given investors something they have wanted for some time: a clear pick-up in sales, led by beauty and pharmaceutical demand. The shares have responded, hitting a new one-year high according to a report published on 2 November. Yet the Dividend figures tell a more cautious story, because the speciality chemicals group is paying out far more than it earned on a trailing basis.

A better quarter, an unchanged outlook

Croda reported third-quarter sales of £449.9m, representing organic growth of 6.6%. Reports of the update attributed the improvement to firmer Demand in beauty and pharma, two markets that matter greatly to the group's Investment case. The company left its outlook for the 2026 financial year unchanged, however, so the update was a sign of improving momentum rather than a formal upgrade.

That distinction matters for income investors. A better quarter helps, but the dividend will ultimately be paid from full-year Earnings and cash generation. A separately reported market consensus points to 2026 sales of about £1.77bn, which gives a sense of what the market is expecting from the Business as a whole. Rallying shares also have a simple mechanical effect on income measures, since a higher share price pushes down the Yield available to new buyers.

What the payout figures show

The data here comes from a snapshot dated 7 October 2026, so yields will have moved with the share price since then. At that point, Croda's annual dividend stood at 111.0p per share, with the latest payment at 48.0p. The trailing 12-month yield was 3.4% and the indicated yield 3.3%, a respectable level for a FTSE 100 chemicals company rather than an outstanding one.

The figure that stands out is the Payout Ratio of 194.6%. Put plainly, the trailing dividend was almost twice Earnings Per Share over the period measured. A ratio above 100% means the dividend is not covered by earnings, and it must effectively be supported by cash flow, reserves or Balance Sheet capacity. It is not proof that a cut is coming, because accounting earnings can be depressed by one-off items or a weak part of the cycle, and the snapshot does not break down the cause. But it does leave little room for error if the recovery stalls.

A long record, growing slowly

Against that sits one of the more impressive records in the data. Croda (LSE:CRDA) has paid dividends continuously for 42 years and has raised them for 27 consecutive years. Few companies can show that kind of discipline through several economic cycles, and a board with such a record is likely to be reluctant to break it.

The most recent growth rate, however, shows how much that streak has been tested. Dividend per share rose just 0.9% year on year, which looks more like an effort to keep a record alive than a confident increase. It is the sort of token rise that companies often make when earnings are under pressure, and it leaves real income growth for holders well behind what the headline streak might suggest.

The optimistic reading is that earnings are now beginning to recover towards the dividend, rather than the dividend needing to fall towards earnings. The third-quarter figures give some support to that view, although a single quarter of sales growth cannot settle the matter.

What to watch

The next test is whether the pick-up in beauty and pharma carries through to profit, because cover can only be rebuilt through earnings. Investors will want to see how far the payout ratio falls when full-year results are published, and whether the board again opts for a modest increase to extend its 27-year run. Any shift in the unchanged outlook would also be significant, as would evidence that the rally has already priced in much of the recovery.